Effects of anagrelide on megakaryopoiesis and platelet production

Seminars in Thrombosis and Hemostasis

Volumn 32, Issue 4, 2006, Pages 352-361

  Thiele, Juergen ^a   Kvasnicka, Hans Michael ^a   Schmitt Graeff, Annette ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Anagrelide; Apoptosis; Endoreduplicative capacity; Fibrogenic activity; Hydroxyurea; Maturation defects; Megakaryocytes; Proliferation

Indexed keywords

ANAGRELIDE; CD61 ANTIGEN; CYCLINE; HYDROXYUREA;

APOPTOSIS; ARTICLE; BONE MARROW BIOPSY; CELL MATURATION; CELL PROLIFERATION; CELL SIZE; DISEASE CLASSIFICATION; DRUG EFFECT; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LEUKEMOGENESIS; LONG TERM CARE; MEGAKARYOBLAST; MEGAKARYOCYTE; MEGAKARYOPOIESIS; MONOTHERAPY; MUTAGENICITY; MYELOFIBROSIS; MYELOID METAPLASIA; PLOIDY; PRIORITY JOURNAL; SYSTEMATIC REVIEW; THROMBOCYTE COUNT; THROMBOCYTE LIFESPAN; THROMBOCYTHEMIA; THROMBOCYTOPOIESIS; WORLD HEALTH ORGANIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE MARROW; CELL DIFFERENTIATION; DRUG EVALUATION; HUMANS; HYDROXYUREA; MEGAKARYOCYTES; MUTAGENESIS; MYELOFIBROSIS; PLATELET AGGREGATION INHIBITORS; PLOIDIES; QUINAZOLINES; THROMBOCYTHEMIA, HEMORRHAGIC; THROMBOPOIESIS; WORLD HEALTH ORGANIZATION;

EID: 33745700695     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-942756     Document Type: Article

References (81)

1. Schafer AI. Thrombocytosis. N Engl J Med 2004;350:1211-1219
2. Tefferi A, Murphy S. Current opinion in essential thrombocythemia: pathogenesis, diagnosis, and management. Blood Rev 2001;15:121-131
3. Barbui T, Finazzi G. Risk factors and prevention of vascular complications in polycythemia vera. Semin Thromb Hemost 1997;23:455-461
4. Barbui T. Indications for lowering platelet numbers in essential thrombocythemia. Semin Hematol 2003;40:22-25
5. Barbui T, Finazzi G. Treatment indications and choice of a platelet-lowering agent in essential thrombocythemia. Curr Hematol Rep 2003;2:248-256
6. Griesshammer M, Langer C. Pharmacotherapy of essential thrombocythaemia: economic considerations. Expert Opin Pharmacother 2003;4:1499-1505
7. Pescatore SL, Lindley C. Anagrelide: a novel agent for the treatment of myeloproliferative disorders. Expert Opin Pharmacother 2000;1:537-546
8. Tefferi A, Silverstein MN, Petitt RM, Mesa RA, Solberg LA Jr. Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of actin, efficacy, toxicity, current indications. Semin Thromb Hemost 1997;23:379-383
9. Tefferi A, Elliott MA, Solberg LA Jr, Silverstein MN. New drugs in essential thrombocythemia and polycythemia vera. Blood Rev 1997;11:1-7
10. Silverstein MN, Petitt RM, Solberg LA Jr, Fleming JS, Knight RC, Schacter LP. Anagrelide: a new drug for treating thrombocytosis. N Engl J Med 1988;318:1292-1294
11. Balduini CL, Bertolino G, Noris P, Ascari E. Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders. Haematologica 1992;77:40-43
12. Mazzucconi MG, De Sanctis V, Chistolini A, Dragoni F, Mandelli F. Therapy with anagrelide in patients affected by essential thrombocythemia: preliminary results. Haematologica 1992;77:315-317
13. Petrides PE, Beykirch MK, Trapp OM. Anagrelide, a novel platelet lowering option in essential thrombocythaemia: treatment experience in 48 patients in Germany. Eur J Haematol 1998;61:71-76
14. Bellucci S, Legrand C, Boval B, Drouet L, Caen J. Studies of platelet volume, chemistry and function in patients with essential thrombocythaemia treated with anagrelide. Br J Haematol 1999;104:886-892
15. Silverstein MN, Tefferi A. Treatment of essential thrombocythemia with anagrelide. Semin Hematol 1999;36:23-25
16. Laguna MS, Kornblihtt LI, Marta RF, Michiels JJ, Molinas FC. Effectiveness of anagrelide in the treatment of symptomatic patients with essential thrombocythemia. Clin Appl Thromb Hemost 2000;6:157-161
17. Anagrelide Study Group. Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Am J Med 1992;92:69-76
18. Petitt RM, Silverstein MN, Petrone ME. Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders. Semin Hematol 1997;34:51-54
19. Andersson BS. Essential thrombocythemia: diagnosis and treatment, with special emphasis on the use of anagrelide. Hematology (Am Soc Hematol Educ Program) 2002;7:173-177
20. Solberg LA Jr. Therapeutic options for essential thrombocythemia and polycythemia vera. Semin Oncol 2002;29:10-15
21. Storen EC, Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia. Blood 2001;97:863-866
22. Brooks WG, Stanley DD, Goode JV. Role of anagrelide in the treatment of thrombocytosis. Ann Pharmacother 1999;33: 1116-1118, 1121
23. Petrides PE. Anagrelide: a decade of clinical experience with its use for the treatment of primary thrombocythaemia. Expert Opin Pharmacother 2004;5:1781-1798
24. Dingli D, Tefferi A. A critical review of anagrelide therapy in essential thrombocythemia and related disorders. Leuk Lymphoma 2005;46:641-650
25. Liozon E, Brigaudeau C, Trimoreau F, et al. Is treatment with hydroxyurea leukemogenic in patients with essential thrombocythemia? An analysis of three new cases of leukaemic transformation and review of the literature. Hematol Cell Ther 1997;39:11-18
26. Sterkers Y, Preudhomme C, Lai JL, et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 1998;91:616-622
27. Finazzi G, Barbui T. Treatment of essential thrombocythemia with special emphasis on leukemogenic risk. Ann Hematol 1999;78:389-392
28. Randi ML, Fabris F, Girolami A. Leukemia and myelodysplasia effect of multiple cytotoxic therapy in essential thrombocythemia. Leuk Lymphoma 2000;37:379-385
29. Barbui T. The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both? Semin Hematol 2004;41:15-17
30. Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. Br J Haematol 2000;110:577-583
31. Fruchtman SM. Treatment paradigms in the management of myeloproliferative disorders. Semin Hematol 2004;41:18-22
32. Furgerson JL, Vukelja SJ, Baker WJ, O'Rourke TJ. Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea. Am J Hematol 1996; 51:137-140
33. Higuchi T, Okada S, Mori H, Niikura H, Omine M, Terada H. Leukemic transformation of polycythemia vera and essential thrombocythemia possibly associated with an alkylating agent. Cancer 1995;75:471-477
34. Löfvenberg E, Nordenson I, Wahlin A. Cytogenetic abnormalities and leukemic transformation in hydroxyurea-treated patients with Philadelphia chromosome negative chronic myeloproliferative disease. Cancer Genet Cytogenet 1990;49: 57-67
35. Nielsen I, Hasselbalch HC. Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. Am J Hematol 2003;74:26-31
36. Weinfeld A, Swolin B, Westin J. Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications. Eur J Haematol 1994;52:134-139
37. Abe Andes W, Noveck RJ, Fleming JS. Inhibition of platelet production induced by an antiplatelet drug, anagrelide, in normal volunteers. Thromb Haemost 1984;52:325-328
38. Mazur EM, Rosmarin AG, Sohl PA, Newton JL, Narendran A. Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans. Blood 1992;79:1931-1937
39. Solberg LA Jr, Tefferi A, Oles KJ, et al. The effects of anagrelide on human megakaryocytopoiesis. Br J Haematol 1997;99:174-180
40. Le Bousse-Kerdiles MC, Martyre MC. Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis. Ann Hematol 1999;78:437-444
41. Martyre MC. Critical review of pathogenetic mechanisms in myelofibrosis with myeloid metaplasia. Curr Hematol Rep 2003;2:257-263
42. Schmitt A, Drouin A, Masse JM, Guichard J, Shagraoui H, Cramer EM. Polymorphonuclear neutrophil and megakaryocyte mutual involvement in myelofibrosis pathogenesis. Leuk Lymphoma 2002;43:719-724
43. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005;353:33-45
44. Yoon SY, Li CY, Mesa RA, Tefferi A. Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 1999;106:682-688
45. Tomer A. Effects of anagrelide on in vivo megakaryocyte proliferation and maturation in essential thrombocythemia. Blood 2002;99:1602-1609
46. Tomer A, Friese P, Conklin R, et al. Flow cytometric analysis of megakaryocytes from patients with abnormal platelet counts. Blood 1989;74:594-601
47. Gatter KC, Cordell JL, Turley H, et al. The immunohistological detection of platelets, megakaryocytes and thrombi in routinely processed specimens. Histopathology 1988;13:257-267
48. Thiele J, Wagner S, Dienemann D, Wienhold S, Fischer R, Stein H. Megakaryocyte precursors (promegakaryoblasts and megakaryoblasts) in the normal human bone marrow. An immunohistochemical and morphometric study on routinely processed trephine biopsies. Anal Quant Cytol Histol 1990;12:285-289
49. Thiele J, Wagner S, Degel C, et al. Megakaryocyte precursors (pro- and megakaryoblasts) in bone marrow tissue from patients with reactive thrombocytosis, polycythemia vera and primary (essential) thrombocythemia. An immunomorphometric study. Virchows Arch B Cell Pathol Incl Mol Pathol 1990;58:295-302
50. Ishibashi T, Ruggeri ZM, Harker LA, Burstein SA. Separation of human megakaryocytes by state of differentiation on continuous gradients of Percoll: size and ploidy analysis of cells identified by monoclonal antibody to glycoprotein IIb/IIIa. Blood 1986;67:1286-1292
51. Levene RB, Williams NT, Lamaziere JM, Rabellino EM. Human megakaryocytes. IV. Growth and characterization of clonable megakaryocyte progenitors in agar. Exp Hematol 1987;15:181-189
52. Levine RF, Hazzard KC, Lamberg JD. The significance of megakaryocyte size. Blood 1982;60:1122-1131
53. Williams N, Levine RF. The origin, development and regulation of megakaryocytes. Br J Haematol 1982;52:173-180
54. Queisser U, Queisser W, Spiertz B. Polyploidization of megakaryocytes in normal humans, in patients with idiopathic thrombocytopenia and with pernicious anaemia. Br J Haematol 1971;20:489-501
55. Thiele J, Kvasnicka HM, Fuchs N, Brunnbauer K, Volkwein N, Schmitt-Graeff A. Anagrelide-induced bone marrow changes during therapy of chronic myeloproliferative disorders with thrombocytosis. An immunohistochemical and morphometric study of sequential trephine biopsies. Haematologica 2003;88:1130-1138
56. Hall PA, Levison DA. Review: assessment of cell proliferation in histological material. J Clin Pathol 1990;43:184-192
57. Thiele J, Kvasnicka HM, Ollig S, Schmitt-Graeff A. Anagrelide does not exert a myelodysplastic effect on megakaryopoiesis-a comparative immunohistochemical and morphometric study with hydroxyurea. Histol Histopathol 2005;20:1071-1076
58. Tricot G, De Wolf-Peeters C, Hendrickx B, Verwilghen RL. Bone marrow histology in myelodysplastic syndromes. I. Histological findings in myelodysplastic syndromes and comparison with bone marrow smears. Br J Haematol 1984;57:423-430
59. Delacretaz F, Schmidt PM, Piguet D, Bachmann F, Costa J. Histopathology of myelodysplastic syndromes. The FAB classification (proposals) applied to bone marrow biopsy. Am J Clin Pathol 1987;87:180-186
60. Fox SB, Lorenzen J, Heryet A, Jones M, Gatter KC, Mason DY. Megakaryocytes in myelodysplasia: an immunohistochemical study on bone marrow trephines. Histopathology 1990;17:69-74
61. Rios A, Canizo MC, Sanz MA, et al. Bone marrow biopsy in myelodysplastic syndromes: morphological characteristics and contribution to the study of prognostic factors. Br J Haematol 1990;75:26-33
62. Thiele J, Imbert M, Pierre R. Chronic idiopathic myelofibrosis. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. WHO Classification of Tumours: Tumours of Haematopoietic and Lymphoid Tissue. Lyon, France: IARC Press;2001:35-38
63. Thiele J, Wagner S, Weuste R, et al. An immunomorphometric study on megakaryocyte precursor cells in bone marrow tissue from patients with chronic myeloid leukemia (CML). Eur J Haematol 1990;44:63-70
64. Thiele J, Kvasnicka HM, Schmitt-Graeff A, Diehl V. Bone marrow histopathology following cytoreductive therapy in chronic idiopathic myelofibrosis. Histopathology 2003;43: 470-479
65. Harrison CN. Essential thrombocythemia: challenges and evidence-based management. Br J Haematol 2005;130:153-165
66. Murphy S. Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia. Semin Hematol 1999;36: 9-13
67. Murphy S, Peterson P, Hand H, Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 1997;34: 29-39
68. Pearson TC. Diagnosis and classification of erythrocytoses and thrombocytoses. Baillieres Clin Haematol 1998;11:695-720
69. Florena AM, Tripodo C, Iannitto E, Porcasi R, Ingrao S, Franco V. Value of bone marrow biopsy in the diagnosis of essential thrombocythemia. Haematologica 2004;89:911-919
70. Thiele J, Kvasnicka HM, Zankovich R, Diehl V. Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis. Haematologica 2000;85:1126-1134
71. Thiele J, Kvasnicka HM. Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients. Ann Hematol 2003;82:148-152
72. Imbert M, Pierre R, Thiele J, Vardiman JW, Brunning RD, Flandrin G. Essential thrombocythaemia. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. WHO Classification of Tumours: Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:39-41
73. Buhr T, Busche G, Choritz H, Langer F, Kreipe H. Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced in sequential bone marrow biopsy specimens. Am J Clin Pathol 2003;119:152-158
74. Georgii A, Buesche G, Kreft A. The histopathology of chronic myeloproliferative diseases. Baillieres Clin Haematol 1998;11:721-749
75. Thiele J, Kvasnicka HM, Schmitt-Graeff A, Diehl V. Dynamics of fibrosis in chronic idiopathic (primary) myelofibrosis during therapy: a follow-up study on 309 patients. Leuk Lymphoma 2003;44:949-953
76. Thiele J, Kvasnicka HM. Prefibrotic chronic idiopathic myelofibrosis-a diagnostic enigma? Acta Haematol 2004;111:155-159
77. Kreft A, Buche G, Ghalibafian M, Buhr T, Fischer T, Kirkpatrick CJ. The incidence of myelofibrosis in essential thrombocythaemia, polycythaemia vera and chronic idiopathic myelofibrosis: a retrospective evaluation of sequential bone marrow biopsies. Acta Haematol 2005;113:137-143
78. Thiele J, Kvasnicka HM, Dietrich H, et al. Dynamics of bone marrow changes in patients with chronic idiopathic myelofibrosis following allogeneic stem cell transplantation. Histol Histopathol 2005;20:879-889
79. Thiele J, Kvasnicka HM. Clinicopathological criteria for differential diagnosis of thrombocythemias in various MPDs. Semin Thromb Hemost 2006;32:219-230
80. Kvasnicka HM, Thiele J. The impact of clinicopathological studies in staging and survival in ET, PV and IMF. Semin Thromb Hemost 2006;32:362-371
81. Thiele J, Kvasnicka HM, Orazi A. Bone marrow histopathology in myeloproliferative disorders - current diagnostic approach. Semin Hematol 2005;42:184-195